106 related articles for article (PubMed ID: 37133434)
1. Opportunities and challenges surrounding financial models for high-investment medications: A survey of access decision-makers and employers.
Lopata E; Terrone C; Gopalan A
J Manag Care Spec Pharm; 2023 Jul; 29(7):782-790. PubMed ID: 37133434
[No Abstract] [Full Text] [Related]
2. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
[No Abstract] [Full Text] [Related]
3. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
[TBL] [Abstract][Full Text] [Related]
4. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the evolution of 401(k) retirement plans for increased consumerism in health care: an application of behavioral research.
DiCenzo J; Fronstin P
EBRI Issue Brief; 2008 Aug; (320):1, 3-26. PubMed ID: 18724525
[TBL] [Abstract][Full Text] [Related]
6. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
7. AMCP Partnership Forum: Advancing Value-Based Contracting.
J Manag Care Spec Pharm; 2017 Nov; 23(11):1096-1102. PubMed ID: 29083973
[TBL] [Abstract][Full Text] [Related]
8. Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Barlow JF; Yang M; Teagarden JR
Value Health; 2019 Jun; 22(6):642-647. PubMed ID: 31198180
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia population health management: perspectives of and lessons learned from population health decision makers.
Roach M; Lin D; Graf M; Pednekar P; Chou JW; Benson C; Doshi JA
J Manag Care Spec Pharm; 2021 Oct; 27(10-a Suppl):S2-S13. PubMed ID: 34652218
[No Abstract] [Full Text] [Related]
10. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
11. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
[TBL] [Abstract][Full Text] [Related]
12. Evolving provider payment models and patient access to innovative medical technology.
Long G; Mortimer R; Sanzenbacher G
J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
[TBL] [Abstract][Full Text] [Related]
13. Managed care market perspectives on the over-the-counter availability of statins.
Richards MK; Blumenfield S; Lyon RA
J Manag Care Pharm; 2004; 10(6):543-50. PubMed ID: 15548127
[TBL] [Abstract][Full Text] [Related]
14. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Dunlop WCN; Staufer A; Levy P; Edwards GJ
Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
[TBL] [Abstract][Full Text] [Related]
15. Best practices in designing preapproval information engagements for US health care decision makers.
Dodda S; Bannister B; Hydery T; Gorey C; Dunlap S; Mody L
J Manag Care Spec Pharm; 2023 Mar; 29(3):245-250. PubMed ID: 36840953
[TBL] [Abstract][Full Text] [Related]
16. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
Greenapple R
Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
[TBL] [Abstract][Full Text] [Related]
17. Synergies between veterinarians and para-professionals in the public and private sectors: organisational and institutional relationships that facilitate the process of privatising animal health services in developing countries.
Woodford JD
Rev Sci Tech; 2004 Apr; 23(1):115-35; discussion 391-401. PubMed ID: 15200091
[TBL] [Abstract][Full Text] [Related]
18. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies.
Horrow C; Kesselheim AS
Health Aff (Millwood); 2023 Nov; 42(11):1532-1540. PubMed ID: 37931198
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
